Reata Pharmaceuticals, Inc.
RETANASDAQHealthcare
$172.36
+$0.04(+0.02%)
Market Cap$6.6B
P/E Ratio—
52W High$172.46
52W Low$21.83
Reata Pharmaceuticals, Inc. (RETA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RETA · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2023Report Date: Aug 8, 2023EPS Actual
$2.32
Est. $2.88 · -19.4%
Revenue
$0.02B
Est. $0.00B · +18855.0%
Fiscal Period
Q3 FY2023
FY ends December
Report Date
Aug 8, 2023
After Market Close
▼ Miss EPS▲ Beat Revenue
RETA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2024 | Aug 5, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 8, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Feb 22, 2024 | — | — | — | — | — | — |
| ◌ Q4 FY2023 | Nov 14, 2023 | -$2.15 | — | — | — | $0.03B | — |
| ▼ Q3 FY2023 | Aug 8, 2023 | $2.88 | $2.32 | -19.4% | $0.02B | $0.00B | +18855.0% |
| ▲ Q2 FY2023 | May 10, 2023 | $2.34 | $3.14 | +34.2% | $0.00B | $0.00B | +21.9% |
| ▼ Q1 FY2023 | Feb 24, 2023 | -$2.21 | -$2.33 | -5.4% | $0.00B | — | — |
| ▼ Q4 FY2022 | Nov 8, 2022 | $2.35 | $2.16 | -8.1% | $0.00B | — | — |
Q3 FY2024
Aug 5, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 8, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Feb 22, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 14, 2023
EPS Actual
—
EPS Est.
-$2.15
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 8, 2023Miss
EPS Actual
$2.32
EPS Est.
$2.88
EPS Surpr.
-19.4%
Revenue
$0.02B
Q2 FY2023
May 10, 2023Beat
EPS Actual
$3.14
EPS Est.
$2.34
EPS Surpr.
+34.2%
Revenue
$0.00B
Q1 FY2023
Feb 24, 2023Miss
EPS Actual
-$2.33
EPS Est.
-$2.21
EPS Surpr.
-5.4%
Revenue
$0.00B
Q4 FY2022
Nov 8, 2022Miss
EPS Actual
$2.16
EPS Est.
$2.35
EPS Surpr.
-8.1%
Revenue
$0.00B
No analyst estimates available for RETA.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2023 | Aug 8, 2023 | -19.4% | $166.42 | $167.16 | +0.44% |
| ▲ Q2 FY2023 | May 10, 2023 | +34.2% | $105.37 | $90.38 | -14.23% |
| ▼ Q1 FY2023 | Feb 24, 2023 | -5.4% | $50.45 | $44.51 | -11.77% |
| ▼ Q4 FY2022 | Nov 8, 2022 | -8.1% | $34.90 | $40.29 | +15.44% |
| ▲ Q3 FY2022 | Aug 8, 2022 | +6.3% | $35.70 | $24.06 | -32.61% |
| ▼ Q2 FY2022 | May 10, 2022 | -10.2% | $20.71 | $24.42 | +17.91% |
| ▲ Q1 FY2022 | Feb 28, 2022 | +1.7% | $26.13 | $32.74 | +25.30% |
| ▼ Q4 FY2021 | Nov 8, 2021 | -15.1% | $105.32 | $107.08 | +1.67% |
Q3 FY2023+0.44%
Report Date
Aug 8, 2023
EPS Beat/Miss
-19.4%
Price Before
$166.42
Price After
$167.16
Q2 FY2023-14.23%
Report Date
May 10, 2023
EPS Beat/Miss
+34.2%
Price Before
$105.37
Price After
$90.38
Q1 FY2023-11.77%
Report Date
Feb 24, 2023
EPS Beat/Miss
-5.4%
Price Before
$50.45
Price After
$44.51
Q4 FY2022+15.44%
Report Date
Nov 8, 2022
EPS Beat/Miss
-8.1%
Price Before
$34.90
Price After
$40.29
Q3 FY2022-32.61%
Report Date
Aug 8, 2022
EPS Beat/Miss
+6.3%
Price Before
$35.70
Price After
$24.06
Q2 FY2022+17.91%
Report Date
May 10, 2022
EPS Beat/Miss
-10.2%
Price Before
$20.71
Price After
$24.42
Q1 FY2022+25.30%
Report Date
Feb 28, 2022
EPS Beat/Miss
+1.7%
Price Before
$26.13
Price After
$32.74
Q4 FY2021+1.67%
Report Date
Nov 8, 2021
EPS Beat/Miss
-15.1%
Price Before
$105.32
Price After
$107.08
Avg Beat Reaction-7.18%
Avg Miss Reaction+4.74%
Beat Rate3 / 8 quarters
Largest Move-32.61% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RETA ends December
Reata Pharmaceuticals, Inc. (RETA) most recently reported earnings on August 8, 2023 for Q3 FY2023, posting EPS of $2.32 — missing the analyst consensus of $2.88 by -19.4%. The next RETA earnings date is expected around September 1, 2026.
Each quarter, investors track RETA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RETA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RETA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RETA earnings · 5 questionsReata Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. RETA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RETA historically reports after market close (AMC).
RETA earnings datewhen is RETA earningsRETA next earnings datewhen does RETA report earningsRETA earnings calendar
▸ Source: FMP · Reata Pharmaceuticals, Inc. SEC filings · US GAAP · Reata Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026